Current Treatment Options in Cardiovascular Medicine

, Volume 14, Issue 6, pp 571–574

The Problem With Cardiovascular Disease Prevention Guidelines

Invited Commentary
  • 168 Downloads

References and Recommended Reading

  1. 1.
    Steinbrook R. Guidance for guidelines. N Engl J Med. 2007;356(4):331–3.PubMedCrossRefGoogle Scholar
  2. 2.
    Campbell EG, Zinner DE. Disclosing industry relationships–toward an improved federal research policy. N Engl J Med. 2010;363(7):604–6.PubMedCrossRefGoogle Scholar
  3. 3.
    McPherson K. The Cochrane Lecture. The best and the enemy of the good: randomised controlled trials, uncertainty, and assessing the role of patient choice in medical decision making. J Epidemiol Community Health. 1994;48(1):6–15.PubMedCrossRefGoogle Scholar
  4. 4.
    McPherson K, Britton A. Preferences and understanding their effects on health. Qual Health Care. 2001;10 Suppl 1:i61–6.PubMedGoogle Scholar
  5. 5.
    Krumholz H. Medicine in the era of outcomes measurement. Circ Cardiovasc Qual Outcomes. 2009;2(3):141–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–613.PubMedCrossRefGoogle Scholar
  7. 7.
    Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.Google Scholar
  8. 8.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA. 1986;256(20):2823–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled tria. Lancet. 2003;361(9364):1149–58.PubMedCrossRefGoogle Scholar
  12. 12.
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, JUPITER Study Group, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.PubMedCrossRefGoogle Scholar
  13. 13.
    Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (EUROPA). Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–75.PubMedCrossRefGoogle Scholar
  15. 15.
    Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Carvedilol Or Metoprolol European Trial Investigators, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino Jr R, Ferdinand K, African-American Heart Failure Trial Investigators, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail. 2008;1(1):34–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol. 2007;49(1):32–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Robinson JG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol. 2008;101(7):1009–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Izzo Jr JL. Are there benefits of antihypertensive therapy beyond blood pressure lowering? Curr Hypertens Rep. 2010;12(6):440–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Duprez DA, Florea N, Zhong W, Grandits GA, Hawthorne CK, Hoke L, et al. Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations. J Am Soc Hypertens. 2011;5(5):401–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Hayward RA, Krumholz HM. Three Reasons to Abandon Low-Density Lipoprotein Targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes. 2012;5(1):2–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Duprez D, Cohn JN. Identifying early cardiovascular disease to target candidates for treatment. J Clin Hypertens. 2008;10(3):226–31.CrossRefGoogle Scholar
  24. 24.
    Duprez DA, Florea ND, Jones K, Cohn JN. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. J Am Coll Cardiol. 2007;50(9):835–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Cohn JN, Duprez DA. Time to foster a rational approach to preventing cardiovascular morbid events. J Am Coll Cardiol. 2008;52(5):327–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Cardiovascular DivisionUniversity of Minnesota Medical SchoolMinneapolisUSA

Personalised recommendations